Effect of Hemocare Syrup and tablets in Anemia

Efficacy of Hemocare Syrup and Hemocare XT Tablets in Iron Deficiency Anemia Among Women of Reproductive Age: A Randomized, Open Label Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/07/014726

Enrollment

120

Registered

2018-07-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Hemocare Syrup: 10 ml OD After meals for 4 weeks Intervention2: Hemocare XT Tablets: 100 mg OD after meals for 4 weeks Control Intervention1: Placebo and Health Education: Placebo 100

Eligibility

Inclusion criteria

Inclusion criteria: Biochemical parameters: Hb gm%: Serum iron: TIBC (Total iron-binding capacity): >385 Î¼g/dl Transferrin saturation: PCV:

Exclusion criteria

Exclusion criteria: Hemoglobin percentage: Below 6 gm% Pregnant and lactating women. IDA with cardiac complications, diabetes mellitus, renal disorder, acute and chronic blood loss, bleeding disorders, hemoglobinopathies and malignancy. IDA in a case of defective absorption like patients of gastrectomy, gastrojejunostomy, sprue syndrome, etc.

Design outcomes

Primary

Measure	Time frame
Change in Hb valueTimepoint: 0,15th day, 21st day, 30th day	—

Secondary

Measure	Time frame
Number of participants with Adverse Drug Reactions/Adverse Drug EventsTimepoint: 0,15th day, 21st day, 30th day and followed another 1 month	—

Countries

India

Contacts

Public ContactMr M Thuyamani

SRM College of Pharmacy

kslakshmi13@gmail.com914427453160

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026